Antimycobacterial therapy for Crohn's disease: a reanalysis

The Lancet Infectious Diseases

Volumn 8, Issue 6, 2008, Pages 344-

  Behr, Marcel A ^a   Hanley, James ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; CLARITHROMYCIN; CLOFAZIMINE; RIFABUTIN;

CROHN DISEASE; HUMAN; LETTER; MYCOBACTERIUM; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; CLINICAL TRIALS AS TOPIC; CLOFAZIMINE; CROHN DISEASE; HUMANS; RIFABUTIN;

EID: 43849087155     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70104-X     Document Type: Letter

References (4)

1. Selby W., Pavli P., Crotty B., et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132 (2007) 2313-2319
2. Gui G., Thomas P., Tizard M., Lake J., Sanderson J., and Hermon-Taylor J. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 39 (1997) 393-400
3. Sandborn W., Feagan B., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
4. Parkes M., Barrett J., Prescott N., et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 39 (2007) 830-832